Cancer Research Institute Event Calendar



Ana Patricia Gámez hosts the 2021 CRI Virtual Immunotherapy Patient Summit in Spanish

Access Spanish-Language, On-Demand Content from the 2022 CRI Virtual Immunotherapy Patient Summit

Sessions from the 2022 CRI Virtual Immunotherapy Patient Summit in Spanish (Conferencia Virtual CRI de Inmunoterapia para Pacientes con Cáncer) are now available on demand and free of charge.

Moderated by Ana Patricia Gámez, TV host and entrepreneur, the Summit contains informative sessions and fireside chats with experts and doctors like Kurt Schalper, MD, PhD, associate professor of pathology and medicine (Medical Oncology), Yale School of Medicine, and director of the Translational Immuno-Oncology Laboratory, Yale Cancer Center. Panels led by Teresa Rodríguez, host of Univisionarios (Univision News) and Carolina Sarassa, a correspondent for Aquí y Ahora and co-anchor of Univision’s noon newscast Edición Digital included the voices of leading experts like Antoni Ribas, MD, PhD, professor of medicine, surgery, and molecular and medical pharmacology at the University of California Los Angeles (UCLA), director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center, and the chair of the Melanoma Committee at SWOG Cancer Research Network, speaking to the need for information and participation in clinical trials for a future immune to cancer for all patients.

An early diagnosis can change a patient’s cancer journey and overall outcome. Unfortunately, Hispanic men and women are less likely to be diagnosed at an early stage. CRI is leading the charge to help close the immunotherapy information gap for the US Hispanic cancer community by providing in-language research, information, and direct access to clinical trial consultations, where a professional navigator will walk patients and their families through their immunotherapy clinical trial options.

Read more:

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.